Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro

Biochemical and Biophysical Research Communications

Volumn 357, Issue 4, 2007, Pages 1016-1020

  Loges, Sonja ^a   Butzal, Martin ^a   Otten, Jasmin ^a   Schweizer, Michaela ^a   Fischer, Uta ^a   Bokemeyer, Carsten ^a   Hossfeld, Dieter K ^a   Schuch, Gunter ^a   Fiedler, Walter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cilengitide; Endothelial cells; Endothelial progenitor cells; Integrin; Neoangiogenesis

Indexed keywords

CD133 ANTIGEN; CD51 ANTIGEN; CILENGITIDE; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; STEM CELL; TUMOR GROWTH;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SNAKE VENOMS;

EID: 34247895532     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.060     Document Type: Article

References (36)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
2. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
3. Hasan J., Byers R., and Jayson G.C. Intra-tumoural microvessel density in human solid tumours. Br. J. Cancer 86 (2002) 1566-1577
4. Laack E., Scheffler A., Burkholder I., Boeters I., Andritzky B., Schuch G., Gorn M., Vohwinkel G., Edler L., Fiedler W., and Hossfeld D.K. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50 (2005) 51-58
5. Toi M., Bando H., and Kuroi K. The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer 7 (2000) 311-314
6. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 55 (2000) 15-35
7. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2 (2002) 795-803
8. Ma P.C., Blaszkowsky L., Bharti A., Landanyi A., Kraeft S.K., Bruno A., Skarin A.T., Chen L.B., and Salgia R. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 23 (2003) 49-62
9. Mancuso P., Calleri A., Cassi C., Gobbi A., Capillo M., Pruneri G., Martinelli G., and Bertolini F. Circulating endothelial cells as a novel marker of angiogenesis. Adv. Exp. Med. Biol. 522 (2003) 83-97
10. Gehling U.M., Ergun S., Schumacher U., Pantel K., Otte M., Schuch G., Schafhausen P., Mende T., Kilic N., Kluge K., Schafer B., Hossfeld D.K., and Fiedler W. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95 (2000) 3106-3112
11. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chatburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A., Hajjar K.A., Manova K., Benezra R., and Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
12. Pelosi E., Valtieri M., Coppola S., Botta R., Gabbianelli M., Lulli V., Marziali G., Masella B., Muller R., Sgadari C., Testa U., Bunnano G., and Peschle C. Identification of the hemangioblast in postnatal life. Blood 100 (2002) 3203-3208
13. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., Kearne M., Magner M., and Isner J.M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85 (1999) 221-228
14. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P.H., and Verfaillie C.M. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109 (2002) 337-346
15. Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., and Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97 (2001) 3658-3661
16. Monestiroli S., Mancuso P., Burlini A., Pruneri G., Dell'Agnola C., Gobbi A., Martinelli G., and Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61 (2001) 4341-4344
17. Loges S., Fehse B., Brockmann M.A., Lamszus K., Butzal M., Guckenbiel M., Ergun S., Fischer U., Zander A.R., Hossfeld D.K., Fiedler W., and Gehling U.M. Identification of the adult human hemangioblast. Stem Cells Dev. 13 (2004) 229-242
18. Butzal M., Loges S., Schweizer M., Fischer U., Gehling U.M., Hossfeld D.K., and Fiedler W. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp. Cell Res. 300 (2004) 65-71
19. Mitjans F., Meyer T., Fittschen C., Goodman S., Jonkczyk A., Marshall J.F., Reyes G., and Piulats J. In vivo therapy of malignant melanoma by means of antagonists of alpha v integrins. Int. J. Cancer 87 (2000) 716-723
20. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., and Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
21. Nisato R.E., Tille J.C., Jonczyk A., Goodman S.L., and Pepper M.S. Alpha v beta 3 and alpha v beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 6 (2003) 105-119
22. Taga T., Suzuki A., Gonzalez-Gomez I., Gilles F.H., Stins M., Shimada H., Barsky L., Weinberg K.I., and Lauq W.E. Alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer 98 (2002) 690-697
23. Eskens F.A., Dumez H., Hoekstra R., Perschl A., Brindley C., Bottcher S., Wynendaele W., Drevs J., Verweij J., and Van Oosterom A.T. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alpha v beta 3 and alpha v beta 5 in patients with advanced solid tumours. Eur. J. Cancer. 39 (2003) 917-926
24. Raguse J.D., Gath H.J., Bier J., Riess H., and Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral. Oncol. 40 (2004) 228-230
25. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonkcyk A., Goodman S.L., and Kessler H. N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists. J. Med. Chem. 42 (1999) 3033-3040
26. Giancotti F.G., and Ruoslahti E. Integrin signaling. Science 285 (1999) 1028-1032
27. Clark E.A., and Brugge J.S. Integrins and signal transduction pathways: the road taken. Science 268 (1995) 233-239
28. LaFlamme S.E., Homan S.M., Bodeau A.L., and Mastrangelo A.M. Integrin cytoplasmic domains as connectors to the cell's signal transduction apparatus. Matrix Biol. 16 (1997) 153-163
29. Schwartz M.A., Schaller M.D., and Ginsberg M.H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol. 11 (1995) 549-599
30. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
31. Short S.M., Talbott G.A., and Juliano R.L. Integrin-mediated signaling events in human endothelial cells. Mol. Biol. Cell 9 (1998) 1969-1980
32. Wijelath E.S., Murray J., Rahman S., Patel Y., Ishida A., Strand K., Azziz S., Cardona C., Hammond W.P., Savidge G.F., Rafii S., and Sobel M. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ. Res. 91 (2002) 25-31
33. Borges E., Jan Y., and Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J. Biol. Chem. 275 (2000) 39867-39873
34. Byzova T.V., Goldman C.K., Pampori N., Thomas K.A., Bett A., Shattil S.J., and Plow E.F. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol. Cell 6 (2000) 851-860
35. Maubant S., Saint-Dizier D., Boutillon M., Perron-Sierra E., Casara P.J., Hickman J.A., Tucker G.C., and Van Obberqhen-Schilling E. Blockade of avb3 and avb5 integrins by RGD mimetics induce anoikis and not integrin-mediated death in human endothelial cells. Blood 108 (2006) 3035-3044
36. Reinmuth N., Liu W., Ahmad S.A., Fan F., Stoeltzing O., Parikh A.A., Bucana C.D., Gallick G.E., Nickols M.A., Westlin W.F., and Ellis L.M. avβ3 Integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 63 (2003) 2079-2087